Статті в журналах з теми "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Minchom, Anna, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Andrew Wotherspoon, Susana Miranda, et al. "Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab." Journal for ImmunoTherapy of Cancer 8, no. 1 (March 2020): e000713. http://dx.doi.org/10.1136/jitc-2020-000713.
Повний текст джерелаMahadevan, Daruka, Li Ma, Kai Treuner, Jenna Wong, and Catherine Schnabel. "330 Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for immune checkpoint inhibitors." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A356. http://dx.doi.org/10.1136/jitc-2021-sitc2021.330.
Повний текст джерелаSokol, Ethan, Natalie Danziger, Dean Pavlick, Julia Andrea Elvin, Jo-Anne Vergilio, Jonathan Keith Killian, Douglas I. Lin, et al. "Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 3558. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3558.
Повний текст джерелаLujambio, Amaia. "The more (mutations), the better." Science Translational Medicine 11, no. 477 (January 30, 2019): eaaw5320. http://dx.doi.org/10.1126/scitranslmed.aaw5320.
Повний текст джерелаHsiehchen, David, Magdalena Espinoza, Cristina Valero, Chul Ahn, and Luc G. T. Morris. "Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups." Journal for ImmunoTherapy of Cancer 9, no. 11 (November 2021): e003683. http://dx.doi.org/10.1136/jitc-2021-003683.
Повний текст джерелаAn, Ho Jung, Hong Jae Chon, and Chan Kim. "Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors." International Journal of Molecular Sciences 22, no. 17 (August 30, 2021): 9414. http://dx.doi.org/10.3390/ijms22179414.
Повний текст джерелаGiordano, Frank A., Marlon R. Veldwijk, Carsten Herskind, and Frederik Wenz. "Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math." Strahlentherapie und Onkologie 194, no. 10 (July 20, 2018): 873–75. http://dx.doi.org/10.1007/s00066-018-1341-z.
Повний текст джерелаDuchemann, Boris, Jordi Remon, Marie Naigeon, Laura Mezquita, Roberto Ferrara, Lydie Cassard, Jean Mehdi Jouniaux, et al. "Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer." Cancers 12, no. 12 (December 3, 2020): 3625. http://dx.doi.org/10.3390/cancers12123625.
Повний текст джерелаAcosta-Medina, Aldo A., Jithma P. Abeykoon, Surendra Dasari, Antonious Z. Hazim, N. Nora Bennani, Terra Lasho, Aishwarya Ravindran, et al. "Tumor Mutational Burden in Histiocytic Neoplasms." Blood 138, Supplement 1 (November 5, 2021): 3634. http://dx.doi.org/10.1182/blood-2021-153128.
Повний текст джерелаBielska, Agata A., Walid K. Chatila, Henry Walch, Nikolaus Schultz, Zsofia K. Stadler, Jinru Shia, Diane Reidy-Lagunes, and Rona Yaeger. "Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance." Journal of the National Comprehensive Cancer Network 19, no. 2 (February 2021): 130–33. http://dx.doi.org/10.6004/jnccn.2020.7680.
Повний текст джерелаSicard, Guillaume, Frédéric Fina, Raphaelle Fanciullino, Fabrice Barlesi, and Joseph Ciccolini. "Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy." Pharmaceutics 12, no. 8 (August 11, 2020): 758. http://dx.doi.org/10.3390/pharmaceutics12080758.
Повний текст джерелаLongo, Vito, Oronzo Brunetti, Amalia Azzariti, Domenico Galetta, Patrizia Nardulli, Francesco Leonetti, and Nicola Silvestris. "Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review." Cancers 11, no. 4 (April 15, 2019): 539. http://dx.doi.org/10.3390/cancers11040539.
Повний текст джерелаHong, Xin, Ryan J. Sullivan, Mark Kalinich, Tanya Todorova Kwan, Anita Giobbie-Hurder, Shiwei Pan, Joseph A. LiCausi, et al. "Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy." Proceedings of the National Academy of Sciences 115, no. 10 (February 16, 2018): 2467–72. http://dx.doi.org/10.1073/pnas.1719264115.
Повний текст джерелаAkhaladze, D. G., G. S. Rabaev, N. V. Zhukov, M. A. Pyatnitskiy, N. S. Gorochov, Y. A. Zhulikov, G. G. Rabaev, A. A. Kasatskiy, I. V. Volodin, and N. V. Myakova. "INITIAL EXPERIENCE IN ESTIMATING TUMOR MUTATION BURDEN IN PEDIATRIC HEPATOCELLULAR CARCINOMA." Pediatria. Journal named after G.N. Speransky 100, no. 3 (May 28, 2021): 193–99. http://dx.doi.org/10.24110/0031-403x-2021-100-3-193-199.
Повний текст джерелаPatel, Amol, Dharmesh Soneji, Purvish Parikh, and Manish Kumar. "Biomarkers in immuno-oncology: A review article." International Journal of Molecular & Immuno Oncology 4 (May 20, 2019): 41–49. http://dx.doi.org/10.25259/ijmio-4-041.
Повний текст джерелаEl-Sayes, Nader, Alyssa Vito, Omar Salem, Samuel Tekeste Workenhe, Yonghong Wan, and Karen Mossman. "A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner." International Journal of Molecular Sciences 23, no. 3 (February 3, 2022): 1754. http://dx.doi.org/10.3390/ijms23031754.
Повний текст джерелаMazloom, Anita, Nima Ghalehsari, Victor Gazivoda, Neil Nimkar, Sonal Paul, Peter Gregos, Janice Rateshwar, and Uqba Khan. "Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies." Journal of Clinical Medicine 9, no. 8 (August 6, 2020): 2533. http://dx.doi.org/10.3390/jcm9082533.
Повний текст джерелаValente, Ana, Amy Gin, Allison Wells, Kai Ding, and Kathleen Moore. "Exploring tumor mutational burden status and clinical benefit of immune checkpoint inhibitors in endometrial cancer." Gynecologic Oncology 164, no. 1 (January 2022): 3–4. http://dx.doi.org/10.1016/j.ygyno.2021.10.046.
Повний текст джерелаKim, Jong Yeob, Andreas Kronbichler, Michael Eisenhut, Sung Hwi Hong, Hans J. van der Vliet, Jeonghyun Kang, Jae Il Shin, and Gabriele Gamerith. "Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis." Cancers 11, no. 11 (November 15, 2019): 1798. http://dx.doi.org/10.3390/cancers11111798.
Повний текст джерелаRauterkus, Grant, Agreen Hadadi, Reagan Barnett, Caroline Weipert, Leylah Drusbosky, Xin Gao, Michael B. Lilly, et al. "Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer." Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022): 165. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.165.
Повний текст джерелаCorrò, Claudia, Valérie Dutoit, and Thibaud Koessler. "Emerging Trends for Radio-Immunotherapy in Rectal Cancer." Cancers 13, no. 6 (March 18, 2021): 1374. http://dx.doi.org/10.3390/cancers13061374.
Повний текст джерелаC Guven, Deniz, Taha K. Sahin, Omer Dizdar, and Saadettin Kilickap. "Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives." Biomarkers in Medicine 14, no. 14 (October 2020): 1383–92. http://dx.doi.org/10.2217/bmm-2020-0310.
Повний текст джерелаOttini, Arianna, Pierangela Sepe, Teresa Beninato, Mélanie Claps, Valentina Guadalupi, Elena Verzoni, Patrizia Giannatempo, Giulia Baciarello, Filippo de Braud, and Giuseppe Procopio. "Biomarker-driven immunotherapy for precision medicine in prostate cancer." Personalized Medicine 19, no. 1 (January 2022): 51–66. http://dx.doi.org/10.2217/pme-2021-0079.
Повний текст джерелаCitra Wahyudin, Hendris Utama, Afriani Afriani, Fenty Anggrainy, and Sabrina Ermayanti. "Immunotherapy in Lung Cancer: A Narrative Literature Review." Bioscientia Medicina : Journal of Biomedicine and Translational Research 7, no. 1 (March 2, 2023): 3024–30. http://dx.doi.org/10.37275/bsm.v7i1.755.
Повний текст джерелаBailey, Nathanael G. "Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement." Genes 13, no. 3 (February 26, 2022): 432. http://dx.doi.org/10.3390/genes13030432.
Повний текст джерелаKinget, Lisa, Oliver Bechter, Kevin Punie, Philip R. Debruyne, Hilde Brems, Paul Clement, Eduard Roussel, et al. "Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors." Current Oncology 28, no. 5 (August 24, 2021): 3227–39. http://dx.doi.org/10.3390/curroncol28050280.
Повний текст джерелаKoustas, Evangelos, Panagiotis Sarantis, Athanasios G. Papavassiliou, and Michalis V. Karamouzis. "The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors." Biomolecules 10, no. 5 (April 25, 2020): 666. http://dx.doi.org/10.3390/biom10050666.
Повний текст джерелаCortellini, Alessio. "The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC." JTO Clinical and Research Reports 1, no. 4 (November 2020): 100080. http://dx.doi.org/10.1016/j.jtocrr.2020.100080.
Повний текст джерелаChen, Nan, Nicole Higashiyama, and Valentina Hoyos. "Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1." Biomedicines 9, no. 12 (December 8, 2021): 1863. http://dx.doi.org/10.3390/biomedicines9121863.
Повний текст джерелаOmuro, Antonio. "Immune-checkpoint inhibitors for glioblastoma: what have we learned?" Arquivos de Neuro-Psiquiatria 80, no. 5 suppl 1 (May 2022): 266–69. http://dx.doi.org/10.1590/0004-282x-anp-2022-s129.
Повний текст джерелаModur, Vishnu, and Fukun Guo. "Tumors bearing defective transcription elongation are immune hot but resistant to immune checkpoint inhibitors." Journal of Immunology 208, no. 1_Supplement (May 1, 2022): 119.11. http://dx.doi.org/10.4049/jimmunol.208.supp.119.11.
Повний текст джерелаSaggese, Pasquale, Cesar Martinez, Linh Tran, Raymond Lim, Camelia Dumitras, Tristan Grogan, David Elashoff, et al. "Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer." Cancers 13, no. 14 (July 18, 2021): 3595. http://dx.doi.org/10.3390/cancers13143595.
Повний текст джерелаChokshi, Chirayu R., Benjamin A. Brakel, Nazanin Tatari, Neil Savage, Sabra K. Salim, Chitra Venugopal, and Sheila K. Singh. "Advances in Immunotherapy for Adult Glioblastoma." Cancers 13, no. 14 (July 7, 2021): 3400. http://dx.doi.org/10.3390/cancers13143400.
Повний текст джерелаPolano, Maurizio, Marco Chierici, Michele Dal Bo, Davide Gentilini, Federica Di Cintio, Lorena Baboci, David L. Gibbs, Cesare Furlanello, and Giuseppe Toffoli. "A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning." Cancers 11, no. 10 (October 15, 2019): 1562. http://dx.doi.org/10.3390/cancers11101562.
Повний текст джерелаGolkaram, Mahdi, Chen Zhao, Kristina Kruglyak, Shile Zhang, and Sven Bilke. "The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy." PLOS Computational Biology 16, no. 11 (November 9, 2020): e1008332. http://dx.doi.org/10.1371/journal.pcbi.1008332.
Повний текст джерелаChen, Krista Y., Aleksandra Popovic, David Hsiehchen, Marina Baretti, Paige Griffith, Ranjan Bista, Azarakhsh Baghdadi, et al. "Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors." Cancers 14, no. 21 (October 30, 2022): 5347. http://dx.doi.org/10.3390/cancers14215347.
Повний текст джерелаMiao, Diana, Claire Margolis, Dylan Martini, Stephanie Anne Mullane, Dana Cullen, Christine Horak, Megan Wind-Rotolo, et al. "Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 3016. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3016.
Повний текст джерелаVivaldi, Caterina, Silvia Catanese, Valentina Massa, Irene Pecora, Francesca Salani, Stefano Santi, Monica Lencioni, Enrico Vasile, Alfredo Falcone, and Lorenzo Fornaro. "Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?" International Journal of Molecular Sciences 21, no. 5 (February 28, 2020): 1658. http://dx.doi.org/10.3390/ijms21051658.
Повний текст джерелаShao, Yusra F., Yasmine Baca, Joanne Xiu, Ari M. Vanderwalde, Gino Kim In, Dave S. B. Hoon, Evidio Domingo-Musibay, et al. "Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 9565. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9565.
Повний текст джерелаShao, Yusra F., Yasmine Baca, Joanne Xiu, Ari M. Vanderwalde, Gino Kim In, Dave S. B. Hoon, Evidio Domingo-Musibay, et al. "Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 9565. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9565.
Повний текст джерелаWang, Shuangkuai, Yuantao Tong, Hui Zong, Xuewen Xu, M. James C. Crabbe, Ying Wang, and Xiaoyan Zhang. "Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types." Genes 13, no. 2 (February 17, 2022): 365. http://dx.doi.org/10.3390/genes13020365.
Повний текст джерелаGhidini, Michele, Angelica Petrillo, Andrea Botticelli, Dario Trapani, Alessandro Parisi, Anna La Salvia, Elham Sajjadi, Roberto Piciotti, Nicola Fusco, and Shelize Khakoo. "How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches." Journal of Clinical Medicine 10, no. 7 (April 1, 2021): 1412. http://dx.doi.org/10.3390/jcm10071412.
Повний текст джерелаLi, Zhenxiang, Jiamao Lin, Lijuan Zhang, Jingchao Li, Yingyun Zhang, Chenglong Zhao, and Haiyong Wang. "Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers." Future Oncology 16, no. 29 (October 2020): 2295–306. http://dx.doi.org/10.2217/fon-2020-0243.
Повний текст джерелаTruong, Cao-Sang, and So Young Yoo. "Oncolytic Vaccinia Virus in Lung Cancer Vaccines." Vaccines 10, no. 2 (February 4, 2022): 240. http://dx.doi.org/10.3390/vaccines10020240.
Повний текст джерелаNgo, Carine, and Sophie Postel-Vinay. "Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments." Biomedicines 10, no. 3 (March 11, 2022): 650. http://dx.doi.org/10.3390/biomedicines10030650.
Повний текст джерелаKosari, Farhad, Maria Disselhorst, Jun Yin, Tobias Peikert, Julia Udell, Sarah Johnson, James Smadbeck, et al. "Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors." Journal of Thoracic Oncology 17, no. 3 (March 2022): 446–54. http://dx.doi.org/10.1016/j.jtho.2021.10.022.
Повний текст джерелаRuiz de Porras, Vicenç, Juan Carlos Pardo, Lucia Notario, Olatz Etxaniz, and Albert Font. "Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?" International Journal of Molecular Sciences 22, no. 9 (April 29, 2021): 4712. http://dx.doi.org/10.3390/ijms22094712.
Повний текст джерелаNandakumar, Vijayalakshmi, and John R. Mills. "The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors." Clinical Chemistry 65, no. 2 (February 1, 2019): 357. http://dx.doi.org/10.1373/clinchem.2018.295097.
Повний текст джерелаSchrock, A. B., C. Ouyang, J. Sandhu, E. Sokol, D. Jin, J. S. Ross, V. A. Miller, et al. "Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer." Annals of Oncology 30, no. 7 (July 2019): 1096–103. http://dx.doi.org/10.1093/annonc/mdz134.
Повний текст джерелаRepáraz, David, Belén Aparicio, Diana Llopiz, Sandra Hervás-Stubbs, and Pablo Sarobe. "Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?" International Journal of Molecular Sciences 23, no. 4 (February 11, 2022): 2022. http://dx.doi.org/10.3390/ijms23042022.
Повний текст джерела